These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9269483)

  • 1. Convolution-based approaches for in vivo-in vitro correlation modeling.
    Gillespie WR
    Adv Exp Med Biol; 1997; 423():53-65. PubMed ID: 9269483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
    Kesisoglou F; Xia B; Agrawal NG
    AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct, differential-equation-based in-vitro-in-vivo correlation (IVIVC) method.
    Buchwald P
    J Pharm Pharmacol; 2003 Apr; 55(4):495-504. PubMed ID: 12803771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
    Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
    J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.
    Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z
    AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers.
    Balan G; Timmins P; Greene DS; Marathe PH
    J Pharm Sci; 2001 Aug; 90(8):1176-85. PubMed ID: 11536222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A convolution-based in vitro-in vivo correlation model for methylphenidate hydrochloride delayed-release and extended-release capsule.
    Gupta PK; Incledon B; Gobburu JVS; Gomeni R
    CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):132-142. PubMed ID: 37864318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computer-based evolutionary search for a nonlinear conversion function for establishing in vitro-in vivo correlation (IVIVC) of oral drug formulations.
    Yamashita F; Fujita A; Zhang X; Sasa Y; Mihara K; Hashida M
    Drug Metab Pharmacokinet; 2012; 27(3):280-5. PubMed ID: 22146108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convolution- and Deconvolution-Based Approaches for Prediction of Pharmacokinetic Parameters of Diltiazem Extended-Release Products in Flow-Through Cell Dissolution Tester.
    Taha NF; Emara LH
    AAPS PharmSciTech; 2022 Jul; 23(6):202. PubMed ID: 35882726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods.
    Gomeni R; Bressolle-Gomeni F
    AAPS J; 2020 Apr; 22(3):67. PubMed ID: 32297044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation.
    Ghosh A; Bhaumik UK; Bose A; Mandal U; Gowda V; Chatterjee B; Chakrabarty US; Pal TK
    Biol Pharm Bull; 2008 Oct; 31(10):1946-51. PubMed ID: 18827360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of drug property and product design on in vitro-in vivo correlation of complex modified-release dosage forms.
    Qiu Y; Li X; Duan JZ
    J Pharm Sci; 2014 Feb; 103(2):507-16. PubMed ID: 24338862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 1-step Bayesian predictive approach for evaluating in vitro in vivo correlation (IVIVC).
    Gould AL; Agrawal NG; Goel TV; Fitzpatrick S
    Biopharm Drug Dispos; 2009 Oct; 30(7):366-88. PubMed ID: 19735073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time Scaling for In Vitro-In Vivo Correlation: the Inverse Release Function (IRF) Approach.
    Cardot JM; Lukas JC; Muniz P
    AAPS J; 2018 Aug; 20(6):95. PubMed ID: 30159772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro-in vivo correlation for complex non-oral drug products: Where do we stand?
    Shen J; Burgess DJ
    J Control Release; 2015 Dec; 219():644-651. PubMed ID: 26419305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability.
    Kakhi M; Marroum P; Chittenden J
    Biopharm Drug Dispos; 2013 Jul; 34(5):262-77. PubMed ID: 23097186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers.
    Korhonen O; Kanerva H; Vidgren M; Urtti A; Ketolainen J
    J Control Release; 2004 Mar; 95(3):515-20. PubMed ID: 15023462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate.
    Gonçalves de Lima L; Rossi de Campos D
    Drug Res (Stuttg); 2016 May; 66(5):225-9. PubMed ID: 26697891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
    Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
    AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.